203 related articles for article (PubMed ID: 34415956)
1. NK cells eliminate Epstein-Barr virus bound to B cells through a specific antibody-mediated uptake.
Alari-Pahissa E; Ataya M; Moraitis I; Campos-Ruiz M; Altadill M; Muntasell A; Moles A; López-Botet M
PLoS Pathog; 2021 Aug; 17(8):e1009868. PubMed ID: 34415956
[TBL] [Abstract][Full Text] [Related]
2. Tonsillar CD56brightNKG2A+ NK cells restrict primary Epstein-Barr virus infection in B cells via IFN-γ.
Jud A; Kotur M; Berger C; Gysin C; Nadal D; Lünemann A
Oncotarget; 2017 Jan; 8(4):6130-6141. PubMed ID: 28008151
[TBL] [Abstract][Full Text] [Related]
3. The Epstein-Barr Virus Oncogene EBNA1 Suppresses Natural Killer Cell Responses and Apoptosis Early after Infection of Peripheral B Cells.
Westhoff Smith D; Chakravorty A; Hayes M; Hammerschmidt W; Sugden B
mBio; 2021 Dec; 12(6):e0224321. PubMed ID: 34781735
[TBL] [Abstract][Full Text] [Related]
4. Antibody-Dependent NK Cell Activation Differentially Targets EBV-Infected Cells in Lytic Cycle and Bystander B Lymphocytes Bound to Viral Antigen-Containing Particles.
López-Montañés M; Alari-Pahissa E; Sintes J; Martínez-Rodríguez JE; Muntasell A; López-Botet M
J Immunol; 2017 Jul; 199(2):656-665. PubMed ID: 28630095
[TBL] [Abstract][Full Text] [Related]
5. Two alternate strategies for innate immunity to Epstein-Barr virus: One using NK cells and the other NK cells and γδ T cells.
Djaoud Z; Guethlein LA; Horowitz A; Azzi T; Nemat-Gorgani N; Olive D; Nadal D; Norman PJ; Münz C; Parham P
J Exp Med; 2017 Jun; 214(6):1827-1841. PubMed ID: 28468758
[TBL] [Abstract][Full Text] [Related]
6. Co-infection of Cytomegalovirus and Epstein-Barr Virus Diminishes the Frequency of CD56
Lam JKP; Azzi T; Hui KF; Wong AMG; McHugh D; Caduff N; Chan KH; Münz C; Chiang AKS
Front Immunol; 2020; 11():1231. PubMed ID: 32625211
[TBL] [Abstract][Full Text] [Related]
7. Induction of the Lytic Cycle Sensitizes Epstein-Barr Virus-Infected B Cells to NK Cell Killing That Is Counteracted by Virus-Mediated NK Cell Evasion Mechanisms in the Late Lytic Cycle.
Williams LR; Quinn LL; Rowe M; Zuo J
J Virol; 2016 Jan; 90(2):947-58. PubMed ID: 26537677
[TBL] [Abstract][Full Text] [Related]
8. Natural Killer cell transcriptome during primary EBV infection and EBV associated Hodgkin Lymphoma in children-A preliminary observation.
M A; Chatterjee S; A P; S M; Davuluri S; Ar AK; T A; M P; Cs P; Sinha M; Chugani A; R VP; Kk A; R S J
Immunobiology; 2020 May; 225(3):151907. PubMed ID: 32044149
[TBL] [Abstract][Full Text] [Related]
9. Impaired cytotoxic T lymphocyte response to Epstein-Barr virus-infected NK cells in patients with severe chronic active EBV infection.
Tsuge I; Morishima T; Kimura H; Kuzushima K; Matsuoka H
J Med Virol; 2001 Jun; 64(2):141-8. PubMed ID: 11360246
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
11. CD21-independent Epstein-Barr virus entry into NK cells.
Lee JH; Choi J; Ahn YO; Kim TM; Heo DS
Cell Immunol; 2018 May; 327():21-25. PubMed ID: 29499908
[TBL] [Abstract][Full Text] [Related]
12. Extranodal NK/T-Cell Lymphomas: The Role of Natural Killer Cells and EBV in Lymphomagenesis.
Saleem A; Natkunam Y
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32098335
[No Abstract] [Full Text] [Related]
13. A distinct subpopulation of human NK cells restricts B cell transformation by EBV.
Lünemann A; Vanoaica LD; Azzi T; Nadal D; Münz C
J Immunol; 2013 Nov; 191(10):4989-95. PubMed ID: 24108698
[TBL] [Abstract][Full Text] [Related]
14. Virus-specific peptide dependent NK cell cytotoxicity.
Tong L; Assenmacher M; Zänker KS; Jähn P
Inflamm Allergy Drug Targets; 2014; 13(2):128-33. PubMed ID: 24517290
[TBL] [Abstract][Full Text] [Related]
15. Role of human natural killer cells during Epstein-Barr virus infection.
Münz C
Crit Rev Immunol; 2014; 34(6):501-7. PubMed ID: 25597312
[TBL] [Abstract][Full Text] [Related]
16. Tonsilar NK cells restrict B cell transformation by the Epstein-Barr virus via IFN-gamma.
Strowig T; Brilot F; Arrey F; Bougras G; Thomas D; Muller WA; Münz C
PLoS Pathog; 2008 Feb; 4(2):e27. PubMed ID: 18266470
[TBL] [Abstract][Full Text] [Related]
17. EBV induces persistent NF-κB activation and contributes to survival of EBV-positive neoplastic T- or NK-cells.
Takada H; Imadome KI; Shibayama H; Yoshimori M; Wang L; Saitoh Y; Uota S; Yamaoka S; Koyama T; Shimizu N; Yamamoto K; Fujiwara S; Miura O; Arai A
PLoS One; 2017; 12(3):e0174136. PubMed ID: 28346502
[TBL] [Abstract][Full Text] [Related]
18. Primary immune responses by cord blood CD4(+) T cells and NK cells inhibit Epstein-Barr virus B-cell transformation in vitro.
Wilson AD; Morgan AJ
J Virol; 2002 May; 76(10):5071-81. PubMed ID: 11967323
[TBL] [Abstract][Full Text] [Related]
19. NTB-A [correction of GNTB-A], a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative disease.
Bottino C; Falco M; Parolini S; Marcenaro E; Augugliaro R; Sivori S; Landi E; Biassoni R; Notarangelo LD; Moretta L; Moretta A
J Exp Med; 2001 Aug; 194(3):235-46. PubMed ID: 11489943
[TBL] [Abstract][Full Text] [Related]
20. Interleukin 15-mediated induction of cytotoxic effector cells capable of eliminating Epstein-Barr virus-transformed/immortalized lymphocytes in culture.
Sharif-Askari E; Fawaz LM; Tran P; Ahmad A; Menezes J
J Natl Cancer Inst; 2001 Nov; 93(22):1724-32. PubMed ID: 11717333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
